Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.69 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.69 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.61 |
| ▸ | PDE4A | P27815 | 3/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.48 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | POLA1 | P09884 | 1/20 | 0.47 |
| ▸ | POLG | P54098 | 1/20 | 0.47 |
| ▸ | FAP | Q12884 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 2/20 | 0.45 |
| ▸ | PDE1A | P54750 | 2/20 | 0.45 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.45 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15257680 | 0.87 | FGFR1 (0.65) | FGFR1SLC22A6P2RY1ABCB11POLA1 | |
| SCHEMBL15449788 | 0.84 | FGFR1 (0.73) | FGFR1SLC22A6P2RY1ABCB11POLA1 | |
| Adefovir SCHEMBL49373 | 0.81 | FGFR1 (1.00) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL29365535 | 0.81 | FGFR1 (1.00) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL7601180 | 0.81 | FGFR1 (0.69) | FGFR1SLC22A6P2RY1ABCB11POLA1 | |
| SCHEMBL15046049 | 0.81 | P2RY1 (0.53) | FGFR1SLC22A6P2RY1PDE4APDE4B | |
| Adefovir SCHEMBL3639260 | 0.81 | FGFR1 (0.97) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL3643715 | 0.81 | FGFR1 (0.97) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL29115272 | 0.81 | FGFR1 (0.97) | FGFR1SLC22A6ABCB11POLA1POLG | |
| Adefovir SCHEMBL439995 | 0.81 | FGFR1 (0.97) | FGFR1SLC22A6ABCB11POLA1POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| US-20140288025-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2013090420-A2 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | FGFR1 710/4885SLC22A6 845/4885P2RY1 3455/4885 |
| US-20140288025-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | FGFR1 710/4885SLC22A6 845/4885P2RY1 3455/4885 |
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | FGFR1 710/4885SLC22A6 845/4885P2RY1 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.